The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys

Molecular Biology Reports

Volumn 37, Issue 5, 2010, Pages 2323-2331

  Yar, Atiye Seda ^a   Menevse, Sevda ^a   Alp, Ebru ^a   Helvacioglu, Fatma ^a   Take, Gulnur ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

COX 1; COX 2; Diabetes mellitus; Resveratrol; Streptozotocin

Indexed keywords

CITRATE SODIUM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIMETHYL SULFOXIDE; GLUCOSE; MESSENGER RNA; RESVERATROL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; WISTAR ALBINO GLAXO RAT;

ANIMALS; BODY WEIGHT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; RATS; RATS, WISTAR; RNA, MESSENGER; SOFTWARE; STILBENES;

ANIMALIA; RATTUS; RICE STRIPE VIRUS;

EID: 77955653212     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-009-9737-6     Document Type: Article

References (37)

1. JR Vane YS Bakhle RM Botting 1998 Cyclooxygenase 1 and 2 Annu Rev Pharmacol Toxicol 38 97 120 10.1146/annurev.pharmtox.38.1.97 10.1146/annurev.pharmtox.38.1.97 1:CAS:528:DyaK1cXivF2itro%3D 9597150
2. WL Smith DL DeWitt RM Garavito 2000 Cyclooxygenases: structural, cellular and molecular biology Annu Rev Biochem 69 145 182 10.1146/annurev.biochem.69.1. 145 10.1146/annurev.biochem.69.1.145 1:CAS:528:DC%2BD3cXnt1ajtLg%3D 10966456
3. WL Smith RM Garavito DL DeWitt 1996 Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 J Biol Chem 271 33157 33160 10.1074/jbc.271.52.33157 1:CAS:528:DyaK2sXitFaksg%3D%3D 8969167 (Pubitemid 27010118)
4. RN Dubois SB Abramson L Crofford, et al. 1998 Cyclooxygenase in biology and disease FASEB J 12 1063 1073 1:CAS:528:DyaK1cXlvFWntbY%3D 9737710
5. The Expert Committe on the diagnosis, classification of DM 2004 Report of the expert committe on the diagnosis and classification of DM Diabetes Care 27 5 10 10.2337/diacare.27.2007.S5
6. MA Atkinson NK Maclaren 1994 The pathogenesis of insulin-dependent diabetes mellitus N Engl J Med 331 1428 1436 10.1056/NEJM199411243312107 1:STN:280:DyaK2M%2FlvFagsA%3D%3D 7969282 (Pubitemid 24348358)
7. RP Robertson JS Harmon 2006 Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell Free Radic Biol Med 41 177 184 10.1016/j.freeradbiomed.2005.04.030 10.1016/j.freeradbiomed. 2005.04.030 1:CAS:528:DC%2BD28Xmt1OrsLw%3D 16814095 (Pubitemid 43928495)
8. J Martinez JJ Moreno 2000 Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production Biochem Pharmacol 59 865 870 10.1016/S0006-2952(99)00380-9 10.1016/S0006-2952(99)00380-9 1:CAS:528:DC%2BD3cXpsVWntg%3D%3D 10718345 (Pubitemid 30081710)
9. LM Szewczuk L Forti LA Stivala TM Penning 2004 Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2 J Biol Chem 279 22727 22737 10.1021/np0498410 10.1074/jbc.M314302200 1:CAS:528:DC%2BD2cXjvF2rurk%3D 15020596 (Pubitemid 39602350)
10. L Fremont 2000 Biological effects of resveratrol Life Sci 66 663 673 10.1016/S0024-3205(99)00410-5 10.1016/S0024-3205(99)00410-5 1:CAS:528: DC%2BD3cXntF2jtw%3D%3D 10680575 (Pubitemid 30077860)
11. EN Frankel AL Waterhouse JE Kinsella 1993 Inhibition of human LDL oxidation by resveratrol Lancet 341 1103 1104 10.1016/0140-6736(93)92472-6 10.1016/0140-6736(93)92472-6 1:STN:280:DyaK3s3isFOlsA%3D%3D 8097009
12. L Belguendouz L Fremont MT Gozzelino 1998 Interaction of trans-resveratrol with plasma lipoproteins Biochem Pharmacol 55 811 816 10.1016/S0006-2952(97)00544-3 10.1016/S0006-2952(97)00544-3 1:CAS:528: DyaK1cXitVKhu7g%3D 9586953 (Pubitemid 28319644)
13. CR Pace-Asciak S Hahn EP Diamandis, et al. 1995 The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease Clin Chim Acta 235 207 219 10.1016/0009-8981(95)06045-1 10.1016/0009-8981(95)06045-1 1:CAS:528:DyaK2MXlsFChsbs%3D 7554275
14. M Jang L Cai GO Udeani KV Slowing, et al. 1997 Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 218 220 10.1126/science.275.5297.218 10.1126/science.275.5297.218 1:CAS:528:DyaK2sXks1Sjtw%3D%3D 8985016
15. J Cui B Juhasz A Tosaki, et al. 2002 Cardioprotection with grapes J Cardiovasc Pharmocol 40 762 769 10.1097/00005344-200211000-00014 1:CAS:528:DC%2BD38Xot12mtbo%3D (Pubitemid 36109294)
16. S Pervaiz 2003 Resveratrol: from grapevines to mammalian biology FASEB J 17 1975 1985 10.1096/fj.03-0168rev 10.1096/fj.03-0168rev 1:CAS:528: DC%2BD3sXovFOmtr0%3D 14597667 (Pubitemid 37392442)
17. S Banerjee C Bueso-Ramos BB Aggarwal 2002 Suppression of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kB, cyclooxygenase 2, and matrix metalloprotease 9 Cancer Res 62 4945 4954 1:CAS:528:DC%2BD38Xmslylu7s%3D 12208745
18. J Gusman H Malonne G Atassi 2001 A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol Carcinogenesis 22 1111 1117 10.1093/carcin/22.8.1111 1:CAS:528:DC%2BD3MXlvVSqtbw%3D 11470738
19. K Subbaramaiah WJ Chung P Michaluart, et al. 1998 Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells J Biol Chem 273 21875 21882 10.1074/jbc.273.34.21875 1:CAS:528:DyaK1cXlsFOqsb0%3D 9705326 (Pubitemid 28405365)
20. S Sharma M Anjaneyulu SK Kulkarni K Chopra 2006 Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats Pharmacology 76 69 75 10.1159/000089720 10.1159/000089720 1:CAS:528:DC%2BD28XmsFGnsQ%3D%3D 16286809 (Pubitemid 43131538)
21. HC Su LM Hung JK Chen 2006 Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats Am J Physiol Endocrinol Metab 290 1339 1346 10.1152/ajpendo.00487.2005 10.1152/ajpendo.00487. 2005 (Pubitemid 43847920)
22. MW Pfaffl GW Horgan L Dempfle 2002 Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR Nucleic Acids Res 30 36 10.1093/nar/30.9.e36
23. C Yu YG Shin A Chow, et al. 2002 Human, rat, and mouse metabolism of resveratrol Pharm Res 19 1907 1914 10.1023/A:1021414129280 10.1023/A: 1021414129280 1:CAS:528:DC%2BD38XpsVSjtr4%3D 12523673 (Pubitemid 36016041)
24. V Hebbar G Shen R Hu, et al. 2005 Toxicogenomics of resveratrol in rat liver Life Sci 76 2299 2314 10.1016/j.lfs.2004.10.039 10.1016/j.lfs.2004.10.039 1:CAS:528:DC%2BD2MXhvVGiurk%3D 15748624 (Pubitemid 40313418)
25. JA Crowell PJ Korytko RL Morrissey, et al. 2004 Resveratrol-associated renal toxicity Toxicol Sci 82 614 619 10.1093/toxsci/kfh263 10.1093/toxsci/ kfh263 1:CAS:528:DC%2BD2cXhtVSru7bO 15329443 (Pubitemid 39600090)
26. ME Juan MP Vinardell JM Planas 2002 The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful J Nutr 132 257 260 1:CAS:528:DC%2BD38XhtFGnsrw%3D 11823587
27. AA Bertelli L Giovannini R Stradi, et al. 1998 Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats Drugs Exp Clin Res 24 51 55 1:CAS:528:DyaK1cXjtVWjtr4%3D 9604148
28. W Andlauer J Kolb K Siebert P Fürst 2000 Assessment of resveratrol bioavailability in the perfused small intestine of the rat Drugs Exp Clin Res 26 47 55 1:CAS:528:DC%2BD3cXksVGgsbw%3D 10894555
29. K Marchant 2008 Diabetes and chronic kidney disease: a complex combination Br J Nurs 17 356 361 18414303
30. T Fujisawa H Ikegami T Ogihara 2006 Diabetic complications and their features in the elderly Nippon Rinsho 64 112 116 16408457
31. JM Forbes MT Coughlan ME Cooper 2008 Oxidative stress as a major culprit in kidney disease in diabetes Diabetes 57 1446 1454 10.2337/db08-0057 10.2337/db08-0057 1:CAS:528:DC%2BD1cXnsF2jurs%3D 18511445
32. H Tilg AR Moschen 2008 Inflammatory mechanisms in the regulation of insulin resistance Mol Med 14 222 231 10.2119/2007-00119 10.2119/2007-00119.Tilg 1:CAS:528:DC%2BD1cXksVensrk%3D 18235842
33. JK Kundu YJ Surh 2004 Molecular basis of chemoprevention by resveratrol: NF-κB and AP-1 as potential targets Mutat Res 555 65 80 10.1016/j.mrfmmm.2004.05.019 1:CAS:528:DC%2BD2cXot12hu7c%3D 15476852 (Pubitemid 39345398)
34. JL Wang HF Cheng MZ Zhang JA McKanna RC Harris 1998 Selective increase of cyclooxygenase-2 expression in a model of renal ablation Am J Physiol 275 613 622
35. R Komers JN Lindsley TT Oyama WE Schutzer JF Reed SL Mader S Anderson 2001 Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes J Clin Invest 107 7 889 898 10.1172/JCI10228 1:CAS:528:DC%2BD3MXisFWhtrk%3D 11285308
36. RC Harris JA McKanna Y Akai HR Jacobson RN Dubois MD Breyer 1994 Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction J Clin Invest 94 6 2504 2510 10.1172/JCI117620 1:CAS:528:DyaK2MXisFWgsrk%3D 7989609
37. C Fang Z Jiang DR Tomlinson 1997 Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes: effects of treatment with evening primrose oil or an aldose reductase inhibitor on COX-1 mRNA levels Prostaglandins Leukot Essent Fatty Acids 56 157 163 10.1016/S0952-3278(97)90513-5 1:CAS:528:DyaK2sXht1Ggurc%3D 9051726 (Pubitemid 27076247)